Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03002961 · ClinicalTrials.gov registry record · Phase 1
Single Ascending Dose Study of RBP-6000
A Phase 1 study, sponsored by Indivior.
- Completed
- Registry status
- Phase 1
- Development phase
- 48
- Enrollment target
NCT03002961 is a Phase 1 study that has completed, run by Indivior. The registered enrollment target is 48 participants.
The verdict
NCT03002961, a Phase 1 study, has completed, sponsored by Indivior.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 48 participants
- Enrollment target
Study Summary
A multi-center, open-label, single ascending dose study to enroll opioid dependent treatment-seeking subjects. Subjects to be enrolled into 3 cohorts receiving low, medium and high doses of depot buprenorphine. A fourth cohort will be enrolled to evaluate the PK of RBP-6000 after receiving suboxone tablets for 7 days.
Interventions
- DRUG RBP-6000
- DRUG Suboxone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2012-07 |
| Est. Completion | 2013-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03002961
The ClinicalTrials.gov registry entry for NCT03002961 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Indivior, which has 37 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which RBP-6000 is the first listed.
NCT03002961 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03002961 about?
NCT03002961 is a clinical study titled "Single Ascending Dose Study of RBP-6000". A multi-center, open-label, single ascending dose study to enroll opioid dependent treatment-seeking subjects. Subjects to be enrolled into 3 cohorts receiving low, medium and high doses of depot buprenorphine. A fourth cohort will be enrolled to evaluate the PK of RBP-6000 after receiving suboxone ...
What is the current status of trial NCT03002961?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 48 participants. The study started on 2012-07. Estimated completion is 2013-10.
What interventions are being tested in trial NCT03002961?
The interventions under investigation include: RBP-6000 (DRUG), Suboxone (DRUG).
Who is sponsoring clinical trial NCT03002961?
This trial is sponsored by Indivior, which has 37 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.